Topotecan
From Wikipedia, the free encyclopedia
|
Topotecan
|
|
| Systematic (IUPAC) name | |
| (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9- dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b] quinoline-3,14(4H,12H)-dione monohydrochloride |
|
| Identifiers | |
| CAS number | 119413-54-6 (hydrochloride) |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H23N3O5 •HCl |
| Mol. mass | 457.9 g/mol |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | 35% |
| Metabolism | Hepatic |
| Half life | 2-3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Intravenous infusion, oral |
Topotecan hydrochloride (trade name Hycamtin) is a chemotherapy agent that is a topoisomerase 1 inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.
After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, Topotecan is the first topoisomerase inhibitor for oral use.
[edit] Administration
IV, oral.
[edit] Side effects
- Diarrhea
- Low blood counts
- Susceptibility to infection

